Endometrial Cancer: Risk Factors and Early Diagnosis in Low-Resource Countries

  • Siriwan Tangjitgamol
  • John Kavanagh
  • Mahesh K. Shetty
Chapter

Abstract

Many risk factors are recognized for the development of endometrial ­cancer (EMC). A strong risk factor for hereditary nonpolyposis colonic cancer is an indication for EMC screening. Any women at risk must be counseled and evaluated in detail about their risk for many cancers, especially colonic and EMC. This is usually done in higher levels of health service rather than in a low resource setting. Also, the data concerning risk have been derived in these higher resource settings and are not necessarily transferable to other populations. For EMC, the screening methods ­comprise an annual transvaginal ultrasound beginning at 30–35 years of age and periodic endometrial sampling. EMC screening is not recommended in any woman with low or moderate risk or those without familial predisposition. Nevertheless, patients should be educated for the signs or symptoms suggesting an endometrial lesion, such as postmenopausal bleeding. An endometrial biopsy with a small cannula is considered an initial diagnostic step. This procedure can be performed in an out-patient setting while uterine curettage is reserved for a woman with inadequate, inconclusive, or hyperplasic tissue from endometrial biopsy. Transvaginal ultrasonography may be useful as an adjunct in selected cases depending on the availability, physician training, or resource setting. Hysteroscopy, as a diagnostic and therapeutic maneuver, requires specialized operative skill and may not be available in limited health care environments.

Keywords

Obesity Toxicity Catheter Estrogen Adenocarcinoma 

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMedCrossRefGoogle Scholar
  3. 3.
    Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13:295–308.PubMedCrossRefGoogle Scholar
  4. 4.
    Sorosky JI. Endometrial cancer. Obstet Gynecol. 2008;111:436–47.PubMedCrossRefGoogle Scholar
  5. 5.
    Tangjitgamol S, Anderson BO, See HT, Lertbutsayanukul C, Sirisabya N, Manchana T, et al. Asian Oncology Summit. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10:1119–27.PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008;113:2221–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol. 1989;161:1859–64.PubMedGoogle Scholar
  8. 8.
    Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989;298:147–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10:253–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Aiman J, Forney JP, Parker Jr CR. Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women. Obstet Gynecol. 1986;68:1–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol. 1983;61:403–7.PubMedGoogle Scholar
  13. 13.
    Silverberg SG. Hyperplasia and carcinoma of the endometrium. Semin Diagn Pathol. 1988;5:135–53.PubMedGoogle Scholar
  14. 14.
    Fenoglio CM, Crum CP, Ferenczy A. Endometrial hyperplasia and carcinoma. Are ultrastructural, biochemical and immunocytochemical studies useful in distinguishing between them? Pathol Res Pract. 1982;174:257–84.PubMedCrossRefGoogle Scholar
  15. 15.
    Sherman ME, Silverberg SG. Advances in endometrial pathology. Clin Lab Med. 1995;15:517–43.PubMedGoogle Scholar
  16. 16.
    Silverberg SG. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod Pathol. 2000;13:309–27.PubMedCrossRefGoogle Scholar
  17. 17.
    Kendall BS, Ronnnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well differentiated carcinoma. Am J Surg Pathol. 1998;22:1012–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Trimble C, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ, et al. Concurrent endometrial carcinoma in women with biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106:812–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists. ACOG committee opinion. Tamoxifen and endometrial cancer. Int J Gynecol Obstet. 2006;107:1475–8.CrossRefGoogle Scholar
  20. 20.
    Formander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfverswärd C, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989;2:117–20.CrossRefGoogle Scholar
  21. 21.
    Andersson M, Storm HH, Mouridse HT. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol. 1992;31:259–63.PubMedCrossRefGoogle Scholar
  22. 22.
    Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.PubMedCrossRefGoogle Scholar
  23. 23.
    Curtis RE, Boice Jr JD, Shriner DA, et al. Second cancer after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst. 1996;88:8332–4.Google Scholar
  24. 24.
    Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94:256–66.PubMedCrossRefGoogle Scholar
  25. 25.
    Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11:485–90.PubMedGoogle Scholar
  26. 26.
    Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.PubMedCrossRefGoogle Scholar
  28. 28.
    Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106:2376–81.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang Y, Liu Z, Yu X, Zhang X, Lü S, Chen X, et al. The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol. 2010;117:41–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16:14–22.PubMedGoogle Scholar
  31. 31.
    Ollikainen M, Abdel-Rahman WM, Moisio AL, Lindroos A, Kariola R, Järvelä I, et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol. 2005;23:4609–16.PubMedCrossRefGoogle Scholar
  32. 32.
    Obermair A, Youlden DR, Young JP, Lindor NM, Baron JA, Newcomb P, et al. Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer. 2010;127:2678–84.PubMedCrossRefGoogle Scholar
  33. 33.
    Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104:7–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Parazzini F, Negri E, La Vecchia C, Benzi G, Chiaffarino F, Polatti A, et al. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer. 1998;76:784–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, et al. Low-fat dietary pattern and cancer incidence in the Women’s Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst. 2007;99:1534–43.PubMedCrossRefGoogle Scholar
  36. 36.
    Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004;82:145–8. quiz 265.PubMedCrossRefGoogle Scholar
  37. 37.
    Setiawan VW, Monroe KR, Goodman MT, Kolonel LN, Pike MC, Henderson BE. Alcohol consumption and endometrial cancer risk: the multiethnic cohort. Int J Cancer. 2008;122:634–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Bravi F, Scotti L, Bosetti C, Gallus S, Negri E, La Vecchia C, et al. Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies. Am J Obstet Gynecol. 2009;200:130–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Tang NP, Li H, Qiu YL, Zhou GM, Ma J. Tea consumption and risk of endometrial cancer: a metaanalysis. Am J Obstet Gynecol. 2009;201:605.e1–8.CrossRefGoogle Scholar
  40. 40.
    Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2009;59:27–41.PubMedCrossRefGoogle Scholar
  41. 41.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Brown GJ, St John DJ, Macrae FA, Aittomäki K. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol. 2001;80:346–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296:1507–17.PubMedCrossRefGoogle Scholar
  44. 44.
    Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, et al. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007;25:5158–64.PubMedCrossRefGoogle Scholar
  46. 46.
    Wright TC, Massad S, Dunton C, Spitzer M, Wilkinson EJ, Solomon D, for the 2006 American Society for Colposcopy and Cervical Pathology—sponsored Consensus Conference ASCCP. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346–55.CrossRefGoogle Scholar
  47. 47.
    Sorosky JI. Endometrial Cancer. Obstet Gynecol. 2012;120:383–97.PubMedCrossRefGoogle Scholar
  48. 48.
    Karlsson B, Granberg S, Wikland M, Ylöstalo P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding—a Nordic multicenter study. Am J Obstet Gynecol. 1995;172:1488–94.PubMedCrossRefGoogle Scholar
  49. 49.
    Goldstein S. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am J Obs Gyn. 2009;201:5–11.CrossRefGoogle Scholar
  50. 50.
    Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765–72.PubMedCrossRefGoogle Scholar
  51. 51.
    Lipscomb GH, Lopatine SM, Stovall TG, Ling FW. A randomized comparison of the Pipelle, Accurette, and Explora endometrial sampling devices. Am J Obstet Gynecol. 1994;170:591–4.PubMedGoogle Scholar
  52. 52.
    Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol. 1995;86:38–42.PubMedCrossRefGoogle Scholar
  53. 53.
    Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol. 2004;95:463–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Clark TJ, Mann CH, Shah N, Khan KS, Song F, Gupta JK. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial hyperplasia. Acta Obstet Gynecol Scand. 2001;80:784–93.PubMedCrossRefGoogle Scholar
  55. 55.
    Obermair A, Geramou M, Gucer F, Denison U, Graf AH, Kapshammer E, et al. Impact of hysteroscopy on disease-free survival in clinically stage I endometrial cancer patients. Int J Gynecol Cancer. 2000;10:275–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Nalaboff KM, Pellerito JS, Ben-Levi E. Imaging the endometrium: disease and normal variants. Radiographics. 2001;21:1409–24.PubMedGoogle Scholar
  57. 57.
    Zalud I, Conway C, Schulman H, et al. Endometrial and myometrial thickness and uterine blood low in postmenopausal women: the influence of hormonal replacement therapy and age. J Ultrasound Med. 1993;12:737–41.PubMedGoogle Scholar
  58. 58.
    Fleischer AC. Sonographic assessment of endometrial disorders. Semin Ultrasound CT MR. 1999;20:259–66.PubMedCrossRefGoogle Scholar
  59. 59.
    Sahakain V, Syrop C, Turner D. Endometrial carcinoma: transvaginal ultrasonography prediction of depth of myometrial invasion. Gynecol Oncol. 1991;43:217–9.CrossRefGoogle Scholar
  60. 60.
    Savelli L, Testa AC, Mabrouk M, Zannoni L, Ludovisi M, Seracchioli R, et al. A prospective blinded comparison of the accuracy of transvaginal sonography and frozen section in the assessment of myometrial invasion in endometrial cancer. Gynecol Oncol. 2012;124(3):549–52.PubMedCrossRefGoogle Scholar
  61. 61.
    Ozdemir S, Celik C, Emlik D, Kiresi D, Esen H. Assessment of myometrial invasion in endometrial cancer by transvaginal sonography, Doppler ultrasonography, magnetic resonance imaging and frozen section. Int J Gynecol Cancer. 2009;19(6):1085–90.PubMedCrossRefGoogle Scholar
  62. 62.
    Dubinsky TJ. Value of sonography in the diagnosis of abnormal vaginal bleeding. J Clin Ultrasound. 2004;32:348–53.PubMedCrossRefGoogle Scholar
  63. 63.
    Gull B, Carlsson SA, Karlsson B, et al. Transvaginal ultrasound in the endometrium in women with post-menopausal bleeding: is it always necessary to perform an endometrial biopsy? Am J Obstet Gynecol. 2000;182:509.PubMedCrossRefGoogle Scholar
  64. 64.
    Einerth Y. Vacuum curettage by the Vabrar method: a simple procedure for endometrial diagnosis. Acta Obstet Gynecol Scand. 1982;61:373–6.PubMedGoogle Scholar
  65. 65.
    Lidor A, Ismajovich B, Confino E, David MP. Histopathological findings in 226 women with postmenopausal uterine bleeding. Acta Obstet Gynecol Scand. 1986;65:41–3.PubMedCrossRefGoogle Scholar
  66. 66.
    Ferenczy A, Shore M, Guralnick M, Gelfand MM. The Kevorkian curette: an appraisal of its effectiveness in endometrial evaluation. Obstet Gynecol. 1979;54:262–7.PubMedGoogle Scholar
  67. 67.
    Stovall TG, Photopulos GJ, Poston WM, Ling FW, Sandles LG. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol. 1991;77:954–6.PubMedGoogle Scholar
  68. 68.
    Medverd JR, Dubinsky TJ. Cost analysis model: US versus endometrial biopsy in evaluation of peri- and postmenopausal abnormal vaginal bleeding. Radiology. 2002;222:619–27.PubMedCrossRefGoogle Scholar
  69. 69.
    Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. Am J Obstet Gynecol. 2003;188:401–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Goldstein RB, Bree RL, Benson CB, Benacerraf BR, Bloss JD, Carlos R, et al. Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound—sponsored consensus conference statement. J Ultrasound Med. 2001;20:1025–36.PubMedGoogle Scholar
  71. 71.
    Goldstein SR. Modern evaluation of the endometrium. Obstet Gynecol. 2010;116(1):168–76.PubMedCrossRefGoogle Scholar
  72. 72.
    Burbos N, Musonda P, Crocker SG, Morris EP, Nieto JJ, Duncan TJ. Management of postmenopausal women with vaginal bleeding when the endometrium cannot be visualized. Acta Obstet Gynecol Scand. 2012;91(6):686–91.PubMedCrossRefGoogle Scholar
  73. 73.
    Fleischer AC, Wheeler JE, Lindsay I, et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. Am J Obstet Gynecol. 2001;184:70–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2011;12:38–48.PubMedCrossRefGoogle Scholar
  75. 75.
    Smith-Bindman R, Kerlikowske K, Feldstein VA. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280(17):1510–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Burbos N, Musonda P, Crocker SG, Morris EP, Nieto JJ, Duncan TJ. Outcome of investigations for postmenopausal vaginal bleeding in women under the age of 50 years. Gynecol Oncol. 2012;125(1):120–3.PubMedCrossRefGoogle Scholar
  77. 77.
    Alcazar JL, Galvan R. Three-dimensional power Doppler ultrasound scanning for the prediction of endometrial cancer in women with postmenopausal bleeding and thickened endometrium. Am J Obstet Gynecol. 2009;200:44.e1–6.CrossRefGoogle Scholar
  78. 78.
    Galvan R, Merce L, Jurado M, et al. Three-dimensional power Doppler angiography in endometrial cancer: correlation with tumor characteristics. Ultrasound Obstet Gynecol. 2010;35:723–9.PubMedGoogle Scholar
  79. 79.
    Liu ZZ, Jiang YX, Dai Q, Yang M, Zhu QL, Zhao DC, et al. Imaging of endometrial carcinoma using contrast-enhanced sonography. J Ultrasound Med. 2011;30(11):1519–27.PubMedGoogle Scholar
  80. 80.
    Lieng M, Qvigstad E, Dahl GF, Istre O. Flow differences between endometrial polyps and cancer: a prospective study using intravenous contrast-enhanced transvaginal color flow Doppler and three-dimensional power Doppler ultrasound. Ultrasound Obstet Gynecol. 2008;32(7):935–40.PubMedCrossRefGoogle Scholar
  81. 81.
    Song Y, Yang J, Liu Z, Shen K. Preoperative evaluation of endometrial carcinoma by contrast-enhanced ultrasonography. BJOG. 2009;116(2):294–8; discussion 298–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Ferrazzi E, Zupi E, Leone FP, Savelli L, Omodei U, Moscarini M, et al. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am J Obstet Gynecol. 2009;200:235.e1–6.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Siriwan Tangjitgamol
    • 1
  • John Kavanagh
    • 2
  • Mahesh K. Shetty
    • 3
  1. 1.Department of Obstetrics and GynecologyVajira HospitalBangkokThailand
  2. 2.Department of Obstetrics and GynecologyChulalongkorn UniversityBangkokThailand
  3. 3.Woman’s Center for Breast Care and MRIWoman’s Hospital of TexasHoustonUSA

Personalised recommendations